ABT-263
ABT-263
ABT-263 (pronounced A-B-T-two-six-three), also known as Navitoclax, is a Bcl-2 inhibitor used in the treatment of various types of cancer. It is a synthetic small molecule that mimics the natural BH3-only proteins, which are the body's natural inhibitors of Bcl-2 proteins.
Etymology
The name ABT-263 is derived from the initials of the company that developed it, Abbott Laboratories, and the number 263 is a unique identifier assigned to the compound during its development. The trade name Navitoclax is a combination of the Latin word 'navis' meaning 'ship' and 'clax' derived from the Greek word 'klasis' meaning 'break', symbolizing the drug's ability to navigate and break down cancer cells.
Pharmacology
ABT-263 works by inhibiting the Bcl-2 family of proteins, which are often overexpressed in cancer cells and contribute to the survival and resistance of these cells to apoptosis. By inhibiting these proteins, ABT-263 promotes apoptosis, or programmed cell death, in cancer cells.
Clinical Use
ABT-263 is currently being investigated in clinical trials for the treatment of various types of cancer, including chronic lymphocytic leukemia (CLL), small cell lung cancer (SCLC), and lymphoma. It has shown promising results in early-phase trials, particularly in patients with CLL and SCLC.
Related Terms
- Bcl-2 inhibitor
- BH3-only proteins
- Apoptosis
- Chronic lymphocytic leukemia
- Small cell lung cancer
- Lymphoma
See Also
External links
- Medical encyclopedia article on ABT-263
- Wikipedia's article - ABT-263
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski